Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non‐small cell lung cancer (NSCLC) through inhibition of HIF‐1α

Non‐small cell lung cancer (NSCLC) has a poor prognosis, and effective therapeutic strategies are lacking. The diabetes drug canagliflozin inhibits NSCLC cell proliferation and the mammalian target of rapamycin (mTOR) pathway, which mediates cell growth and survival, but it is unclear whether this d...

Descripción completa

Detalles Bibliográficos
Autores principales: Biziotis, Olga‐Demetra, Tsakiridis, Evangelia Evelyn, Ali, Amr, Ahmadi, Elham, Wu, Jianhan, Wang, Simon, Mekhaeil, Bassem, Singh, Kanwaldeep, Menjolian, Gabe, Farrell, Thomas, Abdulkarim, Bassam, Sur, Ranjan K., Mesci, Aruz, Ellis, Peter, Berg, Tobias, Bramson, Jonathan L, Muti, Paola, Steinberg, Gregory R, Tsakiridis, Theodoros
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620129/
https://www.ncbi.nlm.nih.gov/pubmed/37584455
http://dx.doi.org/10.1002/1878-0261.13508

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620129/
https://www.ncbi.nlm.nih.gov/pubmed/37584455
http://dx.doi.org/10.1002/1878-0261.13508

Ejemplares similares